WO1996032475A2 - Procedes de preparation de proteines de liaison de l'adn - Google Patents

Procedes de preparation de proteines de liaison de l'adn Download PDF

Info

Publication number
WO1996032475A2
WO1996032475A2 PCT/US1996/004783 US9604783W WO9632475A2 WO 1996032475 A2 WO1996032475 A2 WO 1996032475A2 US 9604783 W US9604783 W US 9604783W WO 9632475 A2 WO9632475 A2 WO 9632475A2
Authority
WO
WIPO (PCT)
Prior art keywords
dna
binding
protein
adrl
binding protein
Prior art date
Application number
PCT/US1996/004783
Other languages
English (en)
Inventor
Cheng Cheng
Elton T. Young
Original Assignee
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington filed Critical University Of Washington
Priority to AU54452/96A priority Critical patent/AU5445296A/en
Publication of WO1996032475A2 publication Critical patent/WO1996032475A2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • Genes that are regulated in parallel in response to a particular inducing signal or in a particular tissue appear to contain common DNA sequence elements which are often, but not always, located upstream of the start site of transcription (Maniatis et al . , Science ___:1237-1245, 1987) . These elements, which provide recognition sites for protein transcription factors, play an essential role in the expression of genes. It is believed that transcription factors have increased in number and diversity during evolution by processes such as gene duplication, divergence and exon shuffling (Mitchell et al., Science 2__A:371-378, 1989) . With the increasing complexity of nuclear DNA sequences that accompanied and presumably accounted for evolutionary changes, internal regions in small DNA-binding motifs may have been duplicated to create DNA-binding proteins with greater specificity.
  • RNA-binding proteins One well-characterized family of DNA-binding proteins is the Cys2"His2 class of "zinc finger” proteins, which constitute one of the major classes of DNA-binding proteins in eukaryotes (Berg, Proc. Natl. Acad. Sci . USA £_ ⁇ :91-102, 1988) .
  • the zinc finger motif was so named because of the tandemly repeating pattern observed in the amino acid sequence of the RNA polymerase III transcription factor TFIIIA (Miller et al . , EMBO J. 4.:1609, 1985) .
  • This motif includes approximately twenty- eight to thirty amino acid residues, with two cysteine and two histidine residues serving to stabilize the domain structure by tetrahedral coordination of a single Zn 2+ ion.
  • a region of approximately twelve amino acids between the invariant cysteine-histidine pairs is characterized by scattered basic residues and several conserved hydrophobic residues.
  • Zinc finger motifs can be represented by the consensus sequence Pro- (Tyr/Phe) -Xaa-Cys-Xaa 2 _ 4 -Cys-Xaa- Xaa-Xaa-Phe-Xaa-Xaa 1 -Xaa-Xaa-Xaa 2 -Leu-Xaa-Xaa 3 -His-Xaa 3 _ 4 - His-Thr-Gly-Glu-Lys (SEQ ID NOS:1-6) , wherein each Xaa is individually a variable amino acid (i.e.
  • each Xaa may be different) , subscripts indicate the number of variable amino acids, and superscript numbers denote amino acid residues forming the predominant sequence-specific contacts with DNA.
  • Zinc finger proteins comprise tandem arrays of these motifs. Individual fingers within the array generally associate with three-base-pair subsites in DNA, with the target DNA triplets being contiguous but not usually overlapping. Studies of crystal structure indicate that only one of the two DNA strands is the major contributor to specific binding.
  • the predominant sequence-specific contacts (designated Xaa 1 , Xaa 2 and Xaa 3 above) are located at positions -1, 3 and 6 relative to an alpha helical region of the polypeptide backbone.
  • the orientation of protein and DNA is antiparallel, that is the N-terminal to C-terminal orientation of the contact amino acid residues is antiparallel to the 5' ⁇ 3' orientation of the contacted DNA strand: amino acid: (N)Arg-//-His-//-Arg(C)
  • DNA (3* )G A G(5') .
  • This zinc finger motif has been identified in a number of transcription factors, including Spl (Kadonaga et al. , Cell 5_1:1079-1090, 1987), the Kruppel protein (ReDemann et al. , Nature 332:90-92. 1988) , the yeast ADR1 transcription factor (Hartshorne et al., Nature ___ : 283-287, 1987) and Zif268 (Christy et al., Proc. Natl . A ⁇ a Sci. USA 8 _7B57-7R61. 1988) .
  • the tertiary structures of zinc finger motifs are essentially the same within and among proteins. conserveed structural features include the relative position and size of the alpha helix and the position of the turn between the alpha helix and the reverse beta sheet.
  • Zinc finger proteins form a subset of the transcription factors, proteins that interact with genes to modulate transcription of those genes. Transcriptional regulation results from the combined effects of a number of factors acting in concert to determine the frequency of transcription initiation.
  • Zinc finger-type transcription factors can be classified as transcriptional activators or repressors.
  • Transcriptional activators are believed to function by interacting, directly or indirectly, with components of the basal transcription complex to enhance formation of a pre-initiation complex.
  • Transcriptional repressors are believed to function by altering chromatin structure, by preventing assembly of basal transcription factors, or by inhibiting the function of transcriptional activators.
  • Activators and repressors generally contain both DNA-binding and regulatory domains.
  • Families of activators and repressors can be defined by shared structural characteristics (e.g., an acidic or glutamine- rich activation domain, an alanine-rich domain, or a Kruppel-associated box) , although others do not exhibit obvious similarities to these groupings.
  • DNA-binding proteins are able to recognize and bind to their specific target sequences.
  • a knowledge of these processes would provide the opportunity to manipulate gene expression in such applications as recombinant protein production and gene therapy.
  • the present invention is directed to modified DNA-binding proteins of the zinc finger type, and to methods of preparing and using such modified proteins and genes encoding them.
  • the invention provides a method for preparing a DNA-binding protein having altered binding specificity.
  • the method comprises the steps of (a) selecting a parent DNA-binding protein comprising first and second Cys2 ⁇ HiS2 zinc fingers, wherein the DNA binding specificity of the parent protein is known; (b) adding an additional Cys2 ⁇ His2 zinc finger to the parent protein to produce an altered DNA-binding protein; and (c) determining the DNA binding specificity of the altered DNA-binding protein, wherein the binding specificity of the altered protein is a result of interactions between nucleotides in a target sequence and amino acid residues in each of the first, second, and additional zinc fingers.
  • the additional zinc finger is a duplicate of one of the first and second zinc fingers.
  • the parent DNA-binding protein is a wild-type Saccharomyces cerevisiae ADR1 protein or MIG1 protein.
  • the parent DNA-binding protein is Saccharomyces cerevisiae ADR1 having a mutation in one of the first or second finger ⁇ that changes DNA binding specificity as compared to wild- type Saccharomyces cerevisiae ADR1.
  • the target sequence is from 9 to 15 nucleotides in length.
  • the altered DNA-binding protein has three, four or five Cys2" HiS2 zinc fingers, each of which interacts with the target sequence.
  • the parent DNA- binding protein has two, three or four Cys2 ⁇ His2 zinc fingers.
  • the step of determining the DNA binding specificity of the altered protein can be carried out in vi tro or in vivo.
  • the determining step comprises measuring electrophoretic mobility of a complex of the altered DNA-binding protein and a DNA molecule.
  • the determining step comprises preparing a mixture of the altered DNA-binding protein and a DNA molecule comprising a predicted binding site under conditions suitable for formation of protein-DNA complexes, and measuring complex formation between the altered DNA-binding protein and the DNA molecule, such as by measuring electrophoretic mobility of a complex of the altered DNA-binding protein and the polynucleotide molecule.
  • the determining step comprises (a) preparing a mixture comprising the altered DNA-binding protein and a plurality of DNA molecules under conditions suitable for complex formation between the altered protein and a target DNA molecule, (b) isolating a complex of the altered DNA-binding protein and a target
  • the determining step comprises (a) culturing a first cell into which has been introduced a first DNA construct comprising a reporter gene operably linked to a transcription promoter segment containing a potential target sequence, (b) culturing a second cell into which has been introduced the first DNA construct and a second DNA construct that directs expression of the altered DNA-binding protein, and (c) measuring transcription of the reporter gene in the first and second cells, wherein a difference in relative transcription levels is indicative of binding of the altered DNA-binding protein to the potential target sequence.
  • a DNA-binding protein comprising first and second Cys2-His2 zinc fingers which has been modified to contain an additional Cys2 ⁇ His2 zinc finger, wherein the DNA- binding protein binds to a binding site in DNA, wherein the binding is a result of interactions between nucleotides in the binding site and amino acid residues in each of the first, second, and additional zinc fingers.
  • the DNA-binding protein contains only three zinc fingers.
  • the additional zinc finger is a duplicate of one of the first and second zinc fingers.
  • the DNA-binding protein is a Saccharomyces cerevisiae protein selected from the group consisting of ADR1 and MIG1.
  • the DNA-binding protein is a Saccharomyces cerevisiae ADR1 protein which has been modified to contain a third Cys2 ⁇ HiS2 zinc finger, wherein the ADR1 protein binds to a binding site other than TTGG(A/G)G as a result of interactions between nucleotides in the binding site and amino acid residues in the third zinc finger.
  • the third zinc finger can be a duplicate of a zinc finger in a wild- ype ADR1 protein.
  • the third zinc finger is that of a DNA-binding protein other than ADR1.
  • the ADR1 protein is further modified to contain a fourth Cys2-His2 zinc finger, wherein the fourth zinc finger alters binding specificity of the ADR1 protein.
  • a cultured eukaryotic cell into which has been introduced a gene encoding a DNA-binding protein comprising first and second Cys2 ⁇ His2 zinc fingers, wherein the gene has been modified so that the DNA-binding protein contains an additional Cys2-His2 zinc finger, wherein the DNA-binding protein binds to a binding site in DNA as a result of interactions between nucleotides in the binding site and amino acid residues in each of the first, second, and additional zinc fingers.
  • the cultured eukaryotic cell is a fungal cell, such as a yeast cell or a filamentous fungal cell.
  • the cultured eukaryotic cell is a Saccharomyces cerevisiae cell.
  • the DNA-binding protein is a modified S. cerevisiae ADR1 or MIG1 protein.
  • a first DNA segment encoding a polypeptide of interest operably linked to a second DNA segment comprising a transcription promoter and a binding site for the DNA-binding protein are introduced into the cell, wherein binding of the DNA-binding protein to the binding site stimulates transcription of the first DNA segment.
  • a further aspect of the invention provides a method for preparing a polypeptide of interest comprising the steps of (a) culturing a yeast cell into which has been introduced (i) an ADR1 gene modified to encode a protein containing a third Cys2 ⁇ His2 zinc finger, wherein the ADi.1-encoded protein binds to a binding site other than TTGG(A/G)G as a result of interactions between nucleotides in the binding site and amino acid residues in the third zinc finger; and (ii) a first DNA segment encoding the polypeptide of interest operably linked to a second DNA segment comprising a transcription promoter and a binding site for the ADR1-encoded protein, wherein binding of the ADRl-encoded protein to the binding site stimulates transcription of the first DNA segment, under conditions suitable for expression of the ADR1 gene and the first DNA segment; and (b) isolating the polypeptide of interest from the yeast cell .
  • Another aspect of the invention provides a cultured eukaryotic cell into which has been introduced a gene encoding a chimeric transcription factor comprising a S. cerevisiae ADR1 DNA-binding domain modified to contain a third Cys2 ⁇ His2 zinc finger, wherein the ADR1 DNA- binding domain binds to a binding site other than TTGG(A/G)G as a result of interactions between nucleotides in the binding site and amino acid residues in the third zinc finger, and wherein the chimeric transcription factor further comprises a non-ADRl transcription activation or repression domain operably linked to the DNA-binding domain.
  • the non-ADRl domain is a transcription activation domain from S. cerevisiae GAL4, S. cerevisiae GCN4, or human or mouse SP1.
  • the non-ADRl domain is a steroid receptor family transcription activation domain.
  • the Figure illustrates the structures of wild- type and altered ADRl zinc-finger domains and their binding sites. Standard single-letter abbreviations are used for amino acid residues and nucleotides.
  • the term "gene” is used herein to describe a DNA segment that encodes a polypeptide or protein.
  • the term encompasses naturally occuring and synthetic DNAs (including cDNAs) , as well as copies of such molecules. Genes may or may not include non-coding sequences such as introns, promoters, and other flanking sequences.
  • modified when used herein to describe genes and proteins, indicates that the material has been changed by human intervention so that it differs from the respective parent material. Such modified genes and proteins include the originally modified material as well as copies thereof.
  • a protein may be modified by expressing a modified gene in a cultured cell.
  • the present invention provides methods for altering DNA-binding specificities of proteins containing Cys2-HiS2 zinc fingers.
  • one or more additional zinc fingers are added to a parent zinc finger protein.
  • additional zinc fingers can combine with existing zinc fingers in a protein to provide a new binding specificity wherein amino acid residues in each of the fingers interact with nucleotides in a target DNA sequence so as to alter the binding specificity of the parent protein.
  • altered in vivo binding specificity of the zinc finger proteins is exploited to regulate expression levels of cloned DNAs.
  • the zinc finger motif is characterized by an approximately 28-residue consensus sequence shown in SEQ ID NOS:1-6.
  • SEQ ID NOS:1-6 the sequence of amino acids
  • Those skilled in the art will recognize that not all zinc finger motifs precisely conform to this consensus sequence. It is conventional in the art to portray the DNA-binc'.ing residues of a zinc finger as a three-residue sequence (e.g. Arg-His-Arg) , even though these residues are not contiguous within the protein.
  • the methods of the present invention begin with a selected parent DNA-binding protein comprising first and second Cys2*-His2 zinc fingers.
  • the DNA binding specificity of the parent protein is known, either through prior experimentation or by the application of experimental techniques known in the art, such as DNA migration assays (Carey, J. in Sauer, R.T. (ed.), Methods Enzymol . 208:103-117, 1991), binding site selection and amplification (Blackwell and Weintraub, Science 250 : 1104- 1110, 1990), and phage display ("panning") (Rebar and Pabo, Science 263 : 671-673, 1994; Jamieson et al. , Biochemistry __.- 5689-5695, 1994) .
  • a protein or polypeptide comprising a zinc finger DNA-binding domain is incubated with a plurality of radiolabeled DNA probes under conditions that promote binding of zinc fingers to their recognition sequences within DNA.
  • Typical incubation conditions are 25 mM HEPES pH 7.5, 5 mM MgCl 2 , 10 ⁇ M ZnCl 2 , 1 mM dithiothreitol, 50 mM KC1, 1 ⁇ g/ l dl-dC, 10% glycerol.
  • the binding reaction is allowed to proceed for approximately ten minutes, after which it is electrophoresed on a polyacrylamide gel . A change in the mobility of a labeled probe is indicative of binding.
  • Table 1 lists examples of known zinc finger proteins and their binding specificities.
  • Table 1 lists only a subset of known zinc finger proteins, and that mutants and engineered variants of many zinc finger proteins and zinc finger domains have been characterized. See, for example, Thiesen and Bach, FEBS l____ 2_L__:23-26, 1991; Desjarlais and Berg, Proc. Natl . Acad. Sci. USA __ -.7345-7349, 1992; Nardelli et al . , Wuc. Acids Res. 2_>:4137-4144, 1992; Warriar et al. , J. Biol. Chem. 2 ⁇ __ . :29016-29023, 1994; and Wang et al . , J. Biol. £_____ 2__:10771-10775, 1994. 12
  • binding sites for zinc finger proteins are commonly shown as nucleotide triplets, not all bases within a triplet must contribute equally to binding, and individual zinc fingers within a protein may bind one, two or three bases on the contact strand of the target DNA. Experimental evidence suggests that a two-base binding site is most common. Thus, some bases within binding sites can be varied without complete loss of binding (and binding protein function) .
  • the parent DNA-binding protein may be a native
  • Modified proteins are commonly produced through the application of genetic engineering techniques sue. as site-directed mutagenesis (e.g. Bahl, U.S. Patent No. 4,351,901; Zoller and Smith, ___ 2:479, 1984; Kunkel, Proc. Natl. Acad. Sci. USA £2:488-492, 1985), polymerase chain reaction (Mullis et al. , U.S. Patent No. 4,683,195; Mullis, U.S. Patent No. 4,603,202) or the like. Modified proteins include those altered within one or more of the zinc fingers and those having sequence alterations elsewhere. In the former case, the alteration may or may not affect the DNA-binding specificity of the protein.
  • site-directed mutagenesis e.g. Bahl, U.S. Patent No. 4,351,901; Zoller and Smith, ___ 2:479, 1984; Kunkel, Proc. Natl. Acad. Sci. USA £2:488-492, 1985
  • modified proteins include chimeric DNA-binding proteins wherein a native or altered DNA-binding domain is operably linked to a second domain from another protein, which second domain is an activator or repressor of transcription.
  • a native or altered DNA- binding domain of the S. cerevisiae ADRl protein can be joined to the acidic activation domain of the herpes simplex virus protein VP16 (Triezenberg et al . , Genes Dev. 2:718-729, 1988), the activation domain of S. cerevisiae GAL4 (Leuther et al . , Cell 22:575-585, 1993) or GCN4 (Hope et al .
  • the parent protein may have third, fourth and further zinc fingers. Such third, fourth and further zinc fingers may be naturally occuring in the protein or may be added to the protein as disclosed herein.
  • the present invention thus provides, within one embodiment, methods for adding a plurality of zinc fingers to a DNA- binding protein.
  • an additional CyS2 ⁇ His2 zinc finger is added to the parent protein.
  • the additional zinc finger is added adjacent to one of the zinc fingers of the parent protein, that is the additional finger is connected to an existing finger by the conserved linker peptide found in zinc finger proteins.
  • This linker is characterized by a five-residue consensus sequence, Thr-Gly/Asn-Glu-Lys-Pro (SEQ ID NO:9) .
  • the additional finger can thus be positioned between fingers of the parent protein or at either end of a plurality of contiguous fingers.
  • Suitable methods of manipulation include enzymatic digestion and ligation of DNA segments, loop-out mutagenesis using the polymerase chain reaction (PCR; see Mullis et al., U.S. Patent No. 4,683,195 and Mullis, U.S. Patent No. 4,683,202), and de novo synthesis of DNA molecules, as well as combinations of these methods. See, in general, Sambrook et al. , Molecular Cloning: A Laboratory Manual . 2nd ed. , Cold Spring Harbor Laboratory, 1989. As discussed in more detail below, a DNA segment encoding a DNA-binding fragment of a DNA-binding protein may be modified and subsequently ligated to the remainder of the protein coding sequence.
  • the additional zinc finger can be a duplicate of a zinc finger in the parent protein.
  • the additional zinc finger has the binding specificity of a zinc finger in the parent protein but will differ in amino acid sequence.
  • the additional zinc finger differs from the zinc fingers in the parent protein in both sequence and binding specificity. The present invention thus provides zinc finger proteins having multiple copies of zinc fingers or a plurality of different zinc fingers.
  • binding specificity is defined as the ratio of app for a particular DNA sequence to K app for a random DNA sequence.
  • a protein will be considered to specifically bind a particular sequence when the ratio is at least 10. It is preferred that the ratio be at least 100.
  • Binding affinity is commonly determined by measuring the electrophoretic mobility of a complex of the protein and a double-stranded DNA. Briefly, DNA migration assays are carried out using a known amount of zinc finger protein or polypeptide and varying amounts of labeled target DNA. The protein or polypeptide is incubated with labeled DNA probes, then the incubated mixture is electrophoresed on a gel to allow detection of changes in the mobility of the DNA probes. Changes in mobility indicate the formation of a complex between the protein or fragment and DNA, allowing the calculation of affinities for different DNA sequences and ratios of affinities. The amounts of free DNA and DNA-protein complex are determined by measuring the amounts of radioactivity in each of these components.
  • Such measurements are made by methods known in the art, such as autoradiography followed by quantitative densitometry or phosphor image analysis of the gel .
  • Predictions of DNA-binding specificity may be made on the basis of known specificities. Such predictions can be used to guide the selection of probes to be included in the incubated mixture.
  • a mixture of the altered DNA-binding protein or a DNA- binding fragment thereof and a plurality of double- stranded DNA molecules is prepared.
  • the mixture is incubated under conditions suitable for complex formation between the altered protein and a target polynucleotide.
  • the altered protein will be combined with a mixture of DNA molecules, such as a random sequence pool, and binding is detected using a gel mobility assay.
  • the number of bases in the DNA to be randomized will usually be equal to three times the number of variant zinc fingers in the protein, although if the binding properties of a variant finger or position within the finger are known, fewer positions can be randomized. For example, if only one variant finger is included, only three positions need be randomized.
  • a complex of the altered DNA-binding protein and a target DNA is then isolated.
  • the target DNA is separated from the protein (e.g., by extraction with phenol) and amplified by PCR.
  • the consensus of several selected and amplified DNA sequences is the binding sequence of the DNA-binding protein.
  • this process of binding, isolation and amplification will be repeated using the PCR products of one round as the pool for the next round of selection and continuing until most of the sequences within the pool can be bound by the protein.
  • the sequence of the bound pool sequence (s) is then determined, typically by cloning the DNA into a suitable sequencing vector and sequencing by standard methods. Using this protocol, three rounds of selection resulted in approximately 80% of pool sequences with 8 randomized positions containing the binding site for ADRl fingers.
  • binding specificity of an altered DNA-binding protein can be determined by an in vivo assay. Briefly, a transcription promoter DNA segment containing a potential target sequence (binding site) is joined to a reporter gene so that binding of a DNA-binding protein to the target sequence will alter the transcription level of the reporter.
  • Suitable reporter genes are those that produce a detectable phenotype in the host cell, such as genes encoding enzymes (e.g, 8-galactosidase, luciferase, alcohol dehydrogenase, or amino acid biosynthetic enzymes encoded by, for example, the LEU2 or HIS3 genes of S. cerevisiae) .
  • the promoter should contain only a single potential target site, thus it is preferred to introduce the potential target sequences into a promoter that is not known to contain a binding site for a zinc finger protein.
  • the DNA construct comprising a reporter gene operably linked to a transcription promoter segment containing a potential target sequence is introduced into a first cell
  • the cell is cultured under conditions suitable for expression of introduced DNA, and the level of transcription is measured. It is expected that the level of transcription of the reporter gene in the first cell will be very low, unless a pre-existing, endogenous transcription factor that recognizes the binding site in the reporter construct is present in the cell .
  • SUBSTITUTESHEET(RUkE26) that directs expression of an altered DNA-binding protein are introduced into a second cell which is also cultured, and the level of transcription of the reporter gene is measured.
  • the first and second DNA constructs may be linked or unlinked, and may be autonomously replicating or may integrate into the genome of the host cell.
  • a difference in relative transcription levels between the first and second cells is indicative of binding of the altered DNA- binding protein to the potential target sequence.
  • a ten ⁇ fold difference in reporter transcription or activity between the first and second cells is considered a positive result. If the DNA-binding protein is a transcriptional activator, binding to the target sequence will increase expression of the reporter.
  • Binding of a repressor DNA-binding protein will reduce expression of the reporter.
  • This screening method can be used with chimeric DNA binding proteins, such as those having an activation domain from one protein and an altered DNA- binding domain of another protein, as well as those altered DNA binding proteins that are derived from a single parent protein.
  • This method is also suitable for use in screening libraries of potential target sequences, in which case colonies positive for binding are isolated, and the promoter-reporter construct is sequenced to determine the sequence of the binding site. See also Sauer, R. ⁇ . (ed.), Methods Enzymol ⁇ 2__, 1991.
  • DNA binding specificity in vi tro it is preferred, for convenience and simplicity, to work with a polypeptide that consists essentially of the DNA-binding domain.
  • a DNA segment encoding the DNA-binding domain can be combined with a DNA segment encoding a regulatory domain, the combined segments encoding a DNA-binding regulatory protein.
  • the binding specificity is to be determined by in vivo assay, the DNA-binding domain will, in general, be operably linked to a regulatory domain. Most commonly, a complete DNA-binding protein of interest will be expressed in an in vivo assay system.
  • the present invention further provides DNA molecules encoding altered DNA-binding proteins. These DNA molecules can be introduced into cells according to conventional procedures such that the DNA molecules are expressed and the cells produce the altered proteins.
  • a DNA molecule encoding an altered DNA-binding protein is inserted into an expression vector, where it is operably linked to additional DNA segments that provide for its transcription. Such additional segments include promoter and terminator sequences.
  • An expression vector may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.
  • the term "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g.
  • prokaryotic and eukaryotic cells include prokaryotic cells (e.g., bacteria of the genera Escherichia and Bacillus) , unicellular microorganisms (e.g., yeasts of the genera Saccharomycyes, Pichia, Schizosaccharomyces and Kluyveromyces) , and cells from multicelluar organisms (e.g., mammalian, insect, avian and plant cells) . See, for example, Kawasaki, U.S. Patent No.
  • the altered DNA-binding proteins of the present invention provide a means for regulating levels of gene transcription in eukaryotic cells.
  • a cell that expresses an altered DNA-binding protein is used as a host for expressing one or more additional DNA molecules, particularly DNA molecules encoding proteins or polypeptides of commercial (e.g. industrial or medical) importance.
  • proteins and polypeptides include growth factors, blood clotting factors, cytokines, proteases, lipases, cellulases, transglutaminases, matrix proteins, immunoglobulins, antigens, poly(amino acids), industrial enzymes, etc.
  • a DNA molecule encoding a protein of interest is operably linked, in an expression vector, to a DNA segment encoding a transcription promoter and a binding site for the altered DNA-binding protein. Expression of the DNA-binding protein results in activation or repression of transcription of the additional DNA sequence (s) .
  • s additional DNA sequence
  • Constitutive control is provided in expression systems wherein expression of the DNA binding protein is itself constitutive, thereby allowing one to increase or decrease expression of a protein of interest as necessary. For example, a low level of gene expression can be increased to an economically feasible level through constitutive co- expression of a DNA-binding transcriptional activator.
  • telomeres a DNA-binding transcriptional represser
  • telomeres a DNA-binding transcriptional represser
  • a cell culture can be allowed to grow to high density, at which time expression of a DNA-binding activator is initiated (or expression of a DNA-binding repressor is halted) , thereby stimulating transcription of the additional DNA sequence(s) encoding one or more proteins of interest.
  • Suitable regulated promoters in this regard include T7, lac and ⁇ P j . promoters for use in E. coli ; the GAL1 , ADH2 and CUP1 promoters for use in the yeast Saccharomyces cerevisiae; and tissue-specific promoters for use in higher eukaryotic cells.
  • ADRl is a transcription factor of 1323 amino acids that binds to a sequence in the 5 ' flanking sequence of the ADH2 gene. This binding site is known as an upstream activating sequence, or UAS. Binding of ADRl to UAS1 in the ADH2 gene activates ADH2 transcription. As described below, the ADRl DNA sequence was altered to produce proteins having a third zinc finger. Interactions between the three zinc fingers in the altered proteins and DNA resulted in binding of the altered proteins to sequences other than the TTGG(A/G)G recognition site of the wild- type ADRl. The methods disclosed herein are equally applicable to other DNA-binding proteins of the Cys2*-His2 zinc finger type.
  • Adrlp/F1F1F2 contains an additional finger one.
  • the second polypeptide contains finger one motifs only and was designated Adrlp/FIFIFI ( Figure) .
  • Zinc finger genes were inserted into the expression vector pCQV (Queen, J. Mol . Appl . flpnpf.. _ -. 1-10, 1983) for expression in E. coli essentially as disclosed by Eisen et al . (Mol . Cell. Biol. _ : 4552-4556, 1988).
  • the FI sequence was also cloned using oligonucleotides F1S1 and F2S1 as primers for PCR.
  • the PCR product was digested with SphI , and two copies were cloned in tandem into Sphl - digested pCQVFl to form pCQV/ADRlFlFlFl .
  • Zinc finger proteins were expressed in E. coli MC1061 using pCQV as the expression vector. Protein extracts were prepared essentially as described by Eisen et al. (ibid) and boiled for 15 minutes in 200 mM KC1, 100 ⁇ m ZnCl 2 , 5mM DTT, 10% glycerol, 25 mM HEPES pH 7.5, and 5 mM MgCl2 (A200Z buffer) . The expression of the zinc finger proteins was confirmed by Western blotting using anti-ADRl finger serum as described by Eisen et al . (ibid.) Zinc finger proteins accounted for approximately 60% cf the total protein after the heat treatment as determined by SDS gel electrophoresis and titration of the DNA binding activity using DNA probes.
  • Adrlp/F1F1F2 was tested with several different oligonucleotide probes that contained two copies of the predicted binding site, TTG G(A/G)G G(A/G)G, in inverted orientation, as found in the wild-type ADRl UAS1 (Thukral et al. Mol . Cf.ll . Biol . ⁇ _Igfifi-I R77. 1991) .
  • TTG GGG GGG was synthesized from the template oligonucleotide F1 2 F2
  • SEQ ID NO:15 (zinc finger protein binding site underlined) was labeled with ⁇ 32 P-ATP using polynucleotide kinase and made double stranded using SK-primer as the primer with DNA polymerase.
  • the probe was purified from a 12% polyacrylamide gel. The free and protein-bound probes were isolated after separating them using the DNA migration assay.
  • G(A/G)G G(A/G)G oligonucleotides forming complexes containing both one (CI) and two molecules (CII) of Adrlp/F1F1F2 as did the two-finger protein on its binding site. Quantitation of DNA binding showed that it did not bind at a detectable level to the binding site of the wild- ype two finger protein, TTG GAG.
  • the free and protein-bound probes were isolated after separating them using a DNA migration assay as described above.
  • the DNA sequence was determined as described by Maxam and Gilbert, Methods Enzymol . __ -. 499-560, 1980. Modification of the guanines in the sequence TTG GGG GGG interfered with binding as shown in Table 2, confirming the importance of Arg and His contacts with guanine, and suggesting that the three-finger protein contacts these residues through the major groove as expected.
  • Adrl/F1F1F2 The specificity of Adrl/F1F1F2 was compared to that of the wild-type (Adrl/F1F2) . To compare the specificities of the two proteins, DNA binding assays were carried out in the presence of increasing amounts of "random" DNA. The non-specific association constant of Adrl/F1F2 was found to be appreciably higher than that of Adrl/F1F1F2. The average value of the Specificity, defined as K specific /K non _ specific , was about 2 x 10 2 for Adrl/F1F2 and about 2 x 10 3 for Adrl/F1F1F2 (Table 3) . Thus, Adrl/F1F1F2 has about a ten-fold greater specificity that the wild-type sequence.
  • ADRl containing three finger one motifs did not efficiently recognize its predicted binding site, G(A/G)G G(A/G)G G(A/G)G.
  • the binding site for this protein was determined by a binding site selection and amplification assay (data not shown) .
  • the binding sites that were selectively amplified contained the consensus sequence NG(G/T/A) G(T/C)G GGG (where N represents any nucleotide) . This result was reconfirmed by gel mobility assay using different DNA sequences as probes. In binding this sequence, Adrlp(F1F1F1) would be able to make 7 of the 9 predicted contacts between Arg or His in the fingers and guanine in the DNA.
  • the three identical fingers must be contacting different subsites. Although it is not possible to unambiguously determine from these data which finger is contacting which base pairs in this binding site, it seems likely that the N-terminal finger is contacting a predicted subsite, GGG, that the middle finger is contacting GCG, and that the C-terminal finger is contacting NG(G/T/A) . If this interpretation is correct, the middle subsite contains a C at the central position in place of G or A, a change that prevents binding by wild-type ADRl , and the subsite for the C- terminal finger contains only two positions showing base specificity.
  • Adrlp/F1F1F2 was fused to the Herpes simplex virus VP16 activation domain (Regier et al., PrOC. Natl. Acad. Sci. USA __ : 883-887, 1993;
  • pRSADRl-VP16 is a centromere plasmid based on pRS314 (Guarente et al . , Proc. Natl. Acad. Sci USA 79: 7410-7414, 1982) containing the TRP1 gene as the marker and the ADRl gene fused to VP16 at amino acid codon 172.
  • the VP16 gene codes for its C-terminal activation domain from amino acid 413 to amino acid 490.
  • the EcoRI-BclI fragment from pCQVFlFlF2 which contains the three-finger fragment, was cloned into pRSADRl-VPl6 to form pRSFlFlF2- VP16.
  • Oligonucleotides F1S1 and F160-4 were used for PCR. Oligonucleotide F160-4
  • GGGAAAC_IS£I ⁇ CCCCTAAATTACC-ACTATGGATTTTTTGA ⁇ _S ⁇ I_ ⁇ ICT; SEQ. ID NO:16) introduced a PstI site (underlined) at amino acid codon 160 (in bold letters) , which is in frame with sequence in pRSFlFlF2-VP16.
  • F160-4 also eliminated the original SphI site (in bold and underlined letters) around the amino acid 149 (arginine) codon without changing the amino acid sequence.
  • PCR products were digested with SphI and Pstl and cloned into pRSFlFlF2-VP16 to form mutated zinc fingers.
  • the three-finger protein, Adrlp/FlFlF2-VP16 was an efficient transcriptional activator, and its function in vivo reflected its binding activity determined in vi tro (Table 4) . Its activity differed both qualitatively and quantitatively from that of the two-finger protein. Surprisingly, the three-finger protein activated a reporter containing a single binding site, unlike the two finger protein, which required an inverted repeat at its binding site in order to activate transcription. It was also unexpected that activation promoted by the three- finger fusion protein was about 50 times higher than that promoted by the two-finger fusion protein.
  • pLGK is a 2 ⁇ plasmid with a URA3 gene as the marker and a lacZ gene fused to the CYC1 promoter sequence (Guarente et al., ibid.).
  • the oligonucleotides that contain a single or an inverted repeat binding site for the zinc finger were double stranded and cloned into the Kpn ⁇ -Xho ⁇ site in pLGK.
  • the sequences for the single or inverted repeat DNA binding sites were the same as used in DNA migration assays. Deletion of the Kpn ⁇ -Xho ⁇ fragment in pLGK removes all of the UAS element in the CYC1 promoter.
  • Activation through a single site could be attributable to the VP16 activation domain on the three- finger fusion protein even though the two-finger fusion protein did not show this property.
  • the three-finger DNA binding domain was put into the context of full length Adrlp (containing 1323 amino acids) by substituting the zinc finger domain.
  • the resulting Adrlp(1323) /F1F1F2 activated the reporter gene with its binding site in the UAS element present either as an inverted repeat or as a single site (data not shown) .
  • the ability to activate transcription through a single site is conferred by the DNA binding domain, not by the activation domain.
  • Mutations were introduced into the middle (FI) or the C-terminal finger (F2) in the yeast expression vector containing AD ⁇ 1/F1F1F2-VP16.
  • a mutation of His 118 to Thr in the middle finger conferred a new DNA binding specificity on the protein, allowing it to activate a reporter gene with the sequence TTG GCG GGG in its promoter (F1F1 (H118T)F2; Table 4) .
  • the analogous mutation allowed the protein to bind to and activate from TTG GCG (Thukral et al . , 1992, ibid) .
  • Adrlp/F1F1F2 binds DNA in the predicted manner, with FI contacting a triplet, G(A/G)G, in the three-finger protein as it does in the two-finger protein.
  • Adrlp/FIFI (H118T) F2-VP16 activated through a single site, as did the wild-type version of this three-finger protein, suggesting that it binds tightly in vivo . Mutants representing loss-of-function alleles had phenotypes that depended on their locations.
  • the R143A mutation in finger 2 reduced activity less than two ⁇ fold, while the R115A mutation in the middle finger reduced activity about thirty-fold (F1F1F2 (R143A) -VP16; F1F1(R115A)F2-VP16; Table 4) .
  • Adrlp with just two fingers was completely defective with either of these mutations (Thukral et al. , 1991, ibid) .
  • These data support the DNA binding data that suggested that the middle finger is more important than the N- or C-terminal fingers.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Procédés de préparation de protéines de liaison de l'ADN ayant des caractéristiques de liaison modifiées. La caractéristique de liaison d'une protéine de liaison d'ADN mère comportant un premier et un deuxième motif en doigt de zinc Cys2-His2 est modifiée par l'addition d'un motif en doigt de zinc supplémentaire. La caractéristique modifiée résulte d'interactions entre des nucléotides dans une séquence cible et des résidus d'acides aminés dans chacun des doigts (le premier, le deuxième et les supplémentaires). Les protéines de liaison d'ADN modifiées sont utiles dans le cadre de procédés de préparation de polypeptides.
PCT/US1996/004783 1995-04-12 1996-04-10 Procedes de preparation de proteines de liaison de l'adn WO1996032475A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54452/96A AU5445296A (en) 1995-04-12 1996-04-10 Methods for preparing dna-binding proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42210795A 1995-04-12 1995-04-12
US08/422,107 1995-04-12

Publications (1)

Publication Number Publication Date
WO1996032475A2 true WO1996032475A2 (fr) 1996-10-17

Family

ID=23673421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004783 WO1996032475A2 (fr) 1995-04-12 1996-04-10 Procedes de preparation de proteines de liaison de l'adn

Country Status (2)

Country Link
AU (1) AU5445296A (fr)
WO (1) WO1996032475A2 (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053057A1 (fr) 1997-05-23 1998-11-26 Gendaq Limited Bibliotheque de polypeptides de fixation d'acide nucleique
WO1999042474A2 (fr) * 1998-02-20 1999-08-26 Genome Dynamics, Inc. Procédé permettant la conception de protéines à doigts de zinc se liant à l'adn
WO2000027878A1 (fr) * 1998-11-09 2000-05-18 Gendaq Limited Systeme de criblage de polypeptides a motifs en doigt de zinc, destine a mettre en evidence une certaine capacite de liaison
WO2001053480A1 (fr) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Polypeptides a liaison acide nucleique caracterises par des modules a liaison acide nucleique lies par une liaison flexible
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
WO2002057308A2 (fr) * 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Polypeptides se liant a un acide nucleique
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6790941B2 (en) 1994-01-18 2004-09-14 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US6977154B1 (en) 1998-03-17 2005-12-20 Gendaq Limited Nucleic acid binding proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
USRE39229E1 (en) 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7262055B2 (en) 1998-08-25 2007-08-28 Gendaq Limited Regulated gene expression in plants
US7273923B2 (en) 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7285416B2 (en) 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7566533B2 (en) 2000-11-27 2009-07-28 Intelligent Medical Devices, Inc. Clinically intelligent diagnostic devices and methods
US7585849B2 (en) 1999-03-24 2009-09-08 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790941B2 (en) 1994-01-18 2004-09-14 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
USRE42211E1 (en) 1994-08-20 2011-03-08 Gendaq, Limited Relating to binding proteins for recognition of DNA
US7521241B2 (en) 1994-08-20 2009-04-21 Gendaq Limited Regulated gene expression in plants
USRE39229E1 (en) 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
USRE45795E1 (en) 1994-08-20 2015-11-10 Gendaq, Ltd. Binding proteins for recognition of DNA
USRE42150E1 (en) 1994-08-20 2011-02-15 Gendaq, Limited Binding proteins for recognition of DNA
USRE45721E1 (en) 1994-08-20 2015-10-06 Gendaq, Ltd. Relating to binding proteins for recognition of DNA
US7759059B2 (en) 1997-05-23 2010-07-20 Gendaq Limited, C/O Brobeck Hale And Dorr Nucleic acid binding proteins
EP1982998A1 (fr) 1997-05-23 2008-10-22 Gendaq Limited Protéines à liaison d'acide nucléique
US7241574B2 (en) 1997-05-23 2007-07-10 Gendaq Ltd. Nucleic acid binding proteins
US8617807B2 (en) 1997-05-23 2013-12-31 Gendaq Limited Nucleic acid binding proteins
EP1975233A1 (fr) 1997-05-23 2008-10-01 Gendaq Limited Protéines à liaison d'acide nucléique
US7700523B2 (en) 1997-05-23 2010-04-20 Gendaq Limited Nucleic acid binding polypeptide library
US6746838B1 (en) 1997-05-23 2004-06-08 Gendaq Limited Nucleic acid binding proteins
US6866997B1 (en) 1997-05-23 2005-03-15 Gendaq Limited Nucleic acid binding proteins
WO1998053057A1 (fr) 1997-05-23 1998-11-26 Gendaq Limited Bibliotheque de polypeptides de fixation d'acide nucleique
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
WO1999042474A3 (fr) * 1998-02-20 1999-10-21 Genome Dynamics Inc Procédé permettant la conception de protéines à doigts de zinc se liant à l'adn
WO1999042474A2 (fr) * 1998-02-20 1999-08-26 Genome Dynamics, Inc. Procédé permettant la conception de protéines à doigts de zinc se liant à l'adn
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US7595376B2 (en) 1998-03-02 2009-09-29 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6903185B2 (en) 1998-03-02 2005-06-07 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US7928195B2 (en) 1998-03-02 2011-04-19 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US7153949B2 (en) 1998-03-02 2006-12-26 Massachusetts Institute Of Technology Nucleic acid encoding poly-zinc finger proteins with improved linkers
US6977154B1 (en) 1998-03-17 2005-12-20 Gendaq Limited Nucleic acid binding proteins
US7262055B2 (en) 1998-08-25 2007-08-28 Gendaq Limited Regulated gene expression in plants
WO2000027878A1 (fr) * 1998-11-09 2000-05-18 Gendaq Limited Systeme de criblage de polypeptides a motifs en doigt de zinc, destine a mettre en evidence une certaine capacite de liaison
US6824978B1 (en) 1999-01-12 2004-11-30 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6785613B2 (en) 1999-01-12 2004-08-31 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US9491934B2 (en) 1999-01-12 2016-11-15 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7163824B2 (en) 1999-01-12 2007-01-16 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7177766B2 (en) 1999-01-12 2007-02-13 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7220719B2 (en) 1999-01-12 2007-05-22 Sangamo Biosciences, Inc. Modulation of endogenous gene expression in cells
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US8268618B2 (en) 1999-01-12 2012-09-18 Sangamo Biosciences, Inc. Repressing endogenous CCR5 gene expression in cells using engineered zinc finger proteins
US7788044B2 (en) 1999-01-12 2010-08-31 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6979539B2 (en) 1999-01-12 2005-12-27 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6607882B1 (en) 1999-01-12 2003-08-19 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7985887B2 (en) 1999-01-12 2011-07-26 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6933113B2 (en) 1999-01-12 2005-08-23 Sangamo Biosciences, Inc. Modulation of endogenous gene expression in cells
US8524874B2 (en) 1999-03-24 2013-09-03 Sangamo Biosciences Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7585849B2 (en) 1999-03-24 2009-09-08 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US8383766B2 (en) 1999-03-24 2013-02-26 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7235354B2 (en) 1999-09-14 2007-06-26 Sangamo Biosciences, Inc. Functional genomics using zinc finger proteins
US6777185B2 (en) 1999-09-14 2004-08-17 Sangamo Biosciences, Inc. Functional genomics using zinc finger proteins
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7491531B2 (en) 1999-12-06 2009-02-17 Sangamo Biosciences, Inc. Randomized libraries of zinc finger proteins
US7943553B2 (en) 1999-12-06 2011-05-17 Sangamo Biosciences, Inc. Randomized libraries of zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US7285416B2 (en) 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
WO2001053480A1 (fr) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Polypeptides a liaison acide nucleique caracterises par des modules a liaison acide nucleique lies par une liaison flexible
US7851216B2 (en) 2000-01-24 2010-12-14 Gendaq, Ltd. Methods and compositions for linking binding domains in nucleic acid binding proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7998679B2 (en) 2000-11-27 2011-08-16 Intelligent Medical Devices, Inc. Devices and methods for diagnosis of susceptibility to diseases and disorders
US7566533B2 (en) 2000-11-27 2009-07-28 Intelligent Medical Devices, Inc. Clinically intelligent diagnostic devices and methods
US8883417B2 (en) 2000-11-27 2014-11-11 Intelligent Medical Devices, Inc. Clinically intelligent diagnostic methods utilizing micromixers disposed in wells
US7622250B2 (en) 2000-11-27 2009-11-24 Intelligent Medical Devices, Inc. Clinically intelligent diagnostic devices and methods
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7560440B2 (en) 2000-12-07 2009-07-14 Sangamo Bioschiences, Inc. Regulation of angiogenesis with zinc finger proteins
US7605140B2 (en) 2000-12-07 2009-10-20 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US8071564B2 (en) 2000-12-07 2011-12-06 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7947469B2 (en) 2001-01-22 2011-05-24 Gendaq, Ltd. Modulation of HIV infection
US9238803B2 (en) 2001-01-22 2016-01-19 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US10344271B2 (en) 2001-01-22 2019-07-09 Sangamo Therapeutics, Inc. Modified zinc finger binding proteins
US7273923B2 (en) 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US8680021B2 (en) 2001-01-22 2014-03-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7705139B2 (en) 2001-01-22 2010-04-27 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
WO2002057308A2 (fr) * 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Polypeptides se liant a un acide nucleique
WO2002057308A3 (fr) * 2001-01-22 2003-02-06 Sangamo Biosciences Inc Polypeptides se liant a un acide nucleique
US9234188B2 (en) 2001-01-22 2016-01-12 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US9234187B2 (en) 2001-01-22 2016-01-12 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7939327B2 (en) 2002-08-29 2011-05-10 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes

Also Published As

Publication number Publication date
AU5445296A (en) 1996-10-30

Similar Documents

Publication Publication Date Title
WO1996032475A2 (fr) Procedes de preparation de proteines de liaison de l'adn
Strubin et al. Yeast and human TFIID with altered DNA-binding specificity for TATA elements
CA2303416C (fr) Systeme de trans-activateur reprime pour la caracterisation d'interactions proteine-proteine
Williams et al. Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements.
JP4584840B2 (ja) ジンクフィンガードメイン及びその同定方法
Cowell et al. Transcriptional repression by a novel member of the bZIP family of transcription factors
Kageyama et al. Molecular cloning and characterization of a human DNA binding factor that represses transcription
Sellers et al. Mutations that define the optimal half-site for binding yeast GCN4 activator protein and identify an ATF/CREB-like repressor that recognizes similar DNA sites
Han et al. Synergistic activation and repression of transcription by Drosophila homeobox proteins
Attardi et al. Drosophila tissue-specific transcription factor NTF-1 contains a novel isoleucine-rich activation motif.
Han et al. Mapping of epidermal growth factor-, serum-, and phorbol ester-responsive sequence elements in the c-jun promoter
Gill et al. Mutations that increase the activity of a transcriptional activator in yeast and mammalian cells.
Bardwell et al. Yeast DNA recombination and repair proteins Rad 1 and Radio constitute a complex in vivo mediated by localized hydrophobic domains
Walker et al. Transcriptional activation by the acidic domain of Vmw65 requires the integrity of the domain and involves additional determinants distinct from those necessary for TFIIB binding
Morris et al. The opposite and antagonistic effects of the closely related POU family transcription factors Brn-3a and Brn-3b on the activity of a target promoter are dependent on differences in the POU domain
Wanke et al. The Aspergillus nigerGCN4 homologue, cpcA, is transcriptionally regulated and encodes an unusual leucine zipper
Zhang et al. Regulation of the transcription of a cluster of Bacillus subtilis spore coat genes
Samson et al. Gene activation and DNA binding by Drosophila Ubx and abd-A proteins
Poon et al. The conserved carboxy-terminal domain of Saccharomyces cerevisiae TFIID is sufficient to support normal cell growth
Salmeron Jr et al. GAL4 mutations that separate the transcriptional activation and GAL80-interactive functions of the yeast GAL4 protein.
Breiding et al. Genetic analysis of the bovine papillomavirus E2 transcriptional activation domain
Arcangioli et al. Sap1, a protein that binds to sequences required for mating-type switching, is essential for viability in Schizosaccharomyces pombe
Hanna-Rose et al. Two evolutionarily conserved repression domains in the Drosophila Krüppel protein differ in activator specificity
Dallmann et al. Related repressor specificity of unrelated phages
Murphy et al. Identification of amdX, a new Cys‐2–His‐2 (C2H2) zinc‐finger gene involved in the regulation of the amdS gene of Aspergillus nidulans

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WA Withdrawal of international application
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: CA